Clinical Trials Logo

Dermatofibrosarcoma clinical trials

View clinical trials related to Dermatofibrosarcoma.

Filter by:

NCT ID: NCT00171912 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Start date: September 2004
Phase: Phase 2
Study type: Interventional

This trial is for various types of malignancies which may depend on certain enzymes (tyrosine kinases) for growth. The objective of this study is to assess to what extent imatinib mesylate blocks these enzymes and to assess the effect on the malignancy.

NCT ID: NCT00122473 Completed - Dermatofibrosarcoma Clinical Trials

Imatinib in Dermatofibrosarcoma Protuberans (DFSP)

Start date: January 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether imatinib is effective in the treatment of primary and recurrent dermatofibrosarcoma protuberans (DFSP).

NCT ID: NCT00085475 Completed - Sarcoma Clinical Trials

Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma

Start date: April 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with locally advanced or metastatic dermatofibrosarcoma protuberans or giant cell fibroblastoma.

NCT ID: NCT00084630 Completed - Clinical trials for Recurrent Adult Soft Tissue Sarcoma

Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans

Start date: May 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well imatinib mesylate works in treating patients with locally recurrent or metastatic dermatofibrosarcoma protuberans (DFSP) or transformed fibrosarcomatous DFSP (a type of soft tissue sarcoma). Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth